DOCSLIB.ORG

Adenosine Receptor P1 Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adenosine Receptor P1 Receptor Adenosine Receptor P1 receptor Adenosine receptors (ARs) comprise a group of G protein-coupled receptors (GPCR) which mediate the physiological actions of adenosine. To date, four AR subtypes have been cloned and identified in different tissues. These receptors have distinct localization, signal transduction pathways and different means of regulation upon exposure to agonists. A key property of some of Adenosine receptors is their ability to serve as sensors of cellular oxidative stress, which is transmitted by transcription factors, such as NF-κB, to regulate the expression of ARs. The importance of Adenosine receptors in the regulation of normal and pathological processes such as sleep, the development of cancers and in protection against hearing loss will be examined. www.MedChemExpress.com 1 Adenosine Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators (Rac)-Mirabegron D5 5'-N-Ethylcarboxamidoadenosine ((Rac)-YM178 D5) Cat. No.: HY-14773S (NECA) Cat. No.: HY-103173 (Rac)-Mirabegron D5 ((Rac)-YM178 D5) is a 5'-N-Ethylcarboxamidoadenosine (NECA) is a deuterium labeled (Rac)-Mirabegron. nonselective adenosine receptor agonist. (Rac)-Mirabegron is the racemate of Mirabegron. Mirabegron is a selective β3-adrenoceptor agonist. Purity: >98% Purity: 99.86% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg 8-Cyclopentyl-1,3-dimethylxanthine A2A receptor antagonist 1 Cat. No.: HY-W011955 (CPI-444 analog) Cat. No.: HY-102024 8-Cyclopentyl-1,3-dimethylxanthine (Compound 2a) A2A receptor antagonist 1 (CPI-444 analog) is an is a selective adenosine A1 receptor antagonist antagonist of both adenosine A2A receptor and with Kis of 10.9 nM and 1440 nM for A1 receptor A1 receptor with Ki values of 4 and 264 nM, and A2 receptor, respectively. respectively.</br>. Purity: >98% Purity: 99.81% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg A2AR-agonist-1 A2B receptor antagonist 1 Cat. No.: HY-18776 Cat. No.: HY-U00321 A2AR-agonist-1 is a potent A2AR and ENT1 agonist A2B receptor antagonist 1 is a potent A2B with Ki of 4.39 and 3.47 for A2AR and ENT1. IC50 adenosine receptor antagonist extracted from value: 4.39 and 3.47 (Ki) Target: A2AR and ENT1 patent WO 2009157938 A1 EXAMPLE 9B. A2AR-agonist-1 is a novel dual-action compound, targeting the Adenosine A2A Receptor and Adenosine Transporter for Neuroprotection. Purity: 99.96% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg AB-MECA AB928 Cat. No.: HY-19365 Cat. No.: HY-129393 AB-MECA is a high affinity A3 adenosine receptor AB928 is an orally bioavailable, selective dual agonist, has high affinity for recombinant A1 and adenosine receptor (A2aR/A2bR) antagonist. AB928 A3 receptors. relieves adenosine-mediated immune suppression. AB928 has immunomodulatory and antitumor activities. Purity: 99.10% Purity: 99.30% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10 mM × 1 mL, 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Acefylline Adenosine 5'-monophosphate monohydrate (Theophyllineacetic acid; Theophylline-7-acetic acid) Cat. No.: HY-B1505 (5'-AMP monohydrate) Cat. No.: HY-A0181A Acefylline (Theophyllineacetic acid), a xanthine Adenosine 5'-monophosphate monohydrate is an derivative, is an adenosine receptor antagonist. adenosine A1 receptor agonist. Adenosine Acefylline is a peptidylarginine deiminase (PAD) 5'-monophosphate monohydrate has significant activator. Acefylline is also a bronchodilator, antiviral activity against HSV-1 and HSV-2. which inhibits rat lung cAMP phosphodiesterase isoenzymes. Purity: 99.89% Purity: 99.07% Clinical Data: Launched Clinical Data: Phase 4 Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 500 mg, 1 g 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Adenosine A1 receptor activator T62 Adenosine amine congener Cat. No.: HY-106199 (ADAC) Cat. No.: HY-128064 Adenosine A1 receptor activator T62 is an Adenosine amine congener (ADAC) is a selective A1 allosteric enhancer of adenosine A1 receptor. adenosine receptor agonist, can ameliorate noise- Adenosine A1 receptor activator T62 produces and Cisplatin-induced cochlear injury. Adenosine antinociception in animal models of acute pain and amine congener also has neuroprotective effects. also reduces hypersensitivity in models of inflammatory and nerve-injury pain. Purity: ≥98.0% Purity: 99.23% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg Size: 10 mM × 1 mL, 5 mg Adenosine antagonist-1 Adenosine-2'-monophosphate Cat. No.: HY-100274 (2'-AMP; Adenosine 2'-phosphate; AMP 2'-phosphate) Cat. No.: HY-124151 Adenosine antagonist-1 is an adenosine A3 receptor Adenosine-2'-monophosphate (2'-AMP) is converted (AA3R) antagonist. by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg Aminophylline APNEA Cat. No.: HY-B0140 (N6-[2-(4-Aminophenyl)ethyl]adenosine) Cat. No.: HY-18687 Aminophylline is a competitive and non-selective APNEA (N6-[2-(4-Aminophenyl)ethyl]adenosine) is a phosphodiesterase (PDE) inhibitor. Aminophylline potent, non-selective A3 adenosine receptor is a competitive adenosine receptor antagonist. agonist. Aminophylline has apulmonary vasodilator action as well as a bronchodilator action and has the potential for asthma research. Purity: 99.91% Purity: 95.01% Clinical Data: Launched Clinical Data: Phase 4 Size: 10 mM × 1 mL, 100 mg, 500 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg AZD4635 BAY 60-6583 (HTL1071) Cat. No.: HY-101980 Cat. No.: HY-103171 AZD4635 (HTL1071) is a potent, selective and BAY 60-6583 is a potent and high-affinity agonist orally active adenosine A2A receptor (A2AR) of adenosine A2B receptor (EC50 = 3 nM) antagonist. AZD4635 binds to human A2AR with a over A1, A2A, and A3 receptors. BAY 60-6583 binds Ki of 1.7 nM and shows >30-fold selectivity to mouse, rabbit, and dog A2BAR with Ki values of over other adenosine receptors. 750 nM, 340 nM and 330 nM, respectively. Purity: 99.68% Purity: 99.58% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg BAY-545 Capadenoson Cat. No.: HY-111767 (BAY 68-4986) Cat. No.: HY-14917 BAY-545 is a potent and selective A2B adenosine Capadenoson is a selective agonist of adenosine-A1 receptor antagonist, with an IC50 of 59 nM. receptor. Purity: 97.06% Purity: 99.28% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg www.MedChemExpress.com 3 CGS 15943 CGS 21680 Cat. No.: HY-100678 Cat. No.: HY-13201 CGS 15943 is an orally bioavailable non-xanthine CGS 21680 is a selective adenosine A2A receptor Adenosine Receptor antagonist. Its Ki for human agonist, with a Ki of 27 nM. A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM in transfected CHO cells, respectively. Purity: 99.63% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg Size: 1 mg, 5 mg CGS 21680 Hydrochloride Cirazoline hydrochloride Cat. No.: HY-13201A (LD 3098 hydrochloride) Cat. No.: HY-101300 CGS 21680 Hydrochloride is a selective adenosine Cirazoline hydrochloride (LD 3098 hydrochloride) A2A receptor agonist with a Ki of 27 nM. is a potent competitive full α1A-adrenergic receptor (α1A-AR) agonist (Ki=120 nM) and only a partial agonist at α1B-AR (Ki= 960 nM) and α1D-AR (Ki=660 nM). Purity: 99.70% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 5 mg, 10 mg, 50 mg CPI-444 Derenofylline (V81444; ciforadenant) Cat. No.: HY-101978 (SLV 320) Cat. No.: HY-14858 CPI-444 (V81444) is a potent, orally active and Derenofylline (SLV 320) is a potent, selective and selective adenosine A2A receptor (A2AR) orally active adenosine A1 receptor antagonist, antagonist, which induces antitumor responses. with Ki values of 1 nM, 200 nM and 398 nM for human A1, A3 and A2A receptors respectively. Purity: 99.94% Purity: 98.26% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg Diphylline Doxofylline (Diprophylline) Cat. No.: HY-B0128 Cat. No.: HY-B0004 Diphylline (Diprophylline) is a potent A1/A2 Doxofylline is an antagonist of adenosine A1 adenosine receptor antagonist and cyclic receptor which also inhibits phosphodiesterase IV. nucleotide phosphodiesterase inhibitor. Diphylline, a xanthine derivative, is a bronchodilator and vasodilator drug and has the potential for chronic bronchitis and emphysema. Purity: 99.07% Purity: 99.32% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg Size: 10 mM × 1 mL, 100 mg DPCPX FSCPX (PD 116948) Cat. No.: HY-100937 Cat. No.: HY-116042 DPCPX (PD 116948), a xanthine derivative, is a FSCPX is a potent and selective irreversible highly potent and selective Adenosine A1 receptor antagonist of A1 adenosine receptor (A1AR), 3 antagonist, with a Ki of 0.46 nM in H-CHA with low nanomolar potency for binding to the binding to A1 receptors in rat whole brain A1AR.
Load more

Recommended publications
  • Applying Screening Techniques to Two Orphan Gpcrs
    Universidade de Lisboa Faculdade de Farmácia Deorphanization of receptors: Applying screening techniques to two orphan GPCRs Ana Catarina Rufas da Silva Santos Mestrado Integrado em Ciências Farmacêuticas 2019 Universidade de Lisboa Faculdade de Farmácia Deorphanization of receptors: Applying screening techniques to two orphan GPCRs Ana Catarina Rufas da Silva Santos Monografia de Mestrado Integrado em Ciências Farmacêuticas apresentada à Universidade de Lisboa através da Faculdade de Farmácia Orientadora: Ghazl Al Hamwi, PhD Student Co-Orientadora: Professora Doutora Elsa Maria Ribeiro dos Santos Anes, Professora Associada com Agregação em Microbiologia 2019 Abstract G-Protein Coupled Receptors represent one of the largest families of cellular receptors discovered and one of the main sources of attractive drug targets. In contrast, it also has a large number of understudied or orphan receptors. Pharmacological assays such as β-Arrestin recruitment assays, are one of the possible approaches for deorphanization of receptors. In this work, I applied the assay system previously mentioned to screen compounds in two orphan receptors, GRP37 and MRGPRX3. GPR37 has been primarily associated with a form of early onset Parkinsonism due to its’ expression patterns, and physiological role as substrate to ubiquitin E3, parkin. Although extensive literature regarding this receptor is available, the identification of a universally recognized ligand has not yet been possible. Two compounds were proposed as ligands, but both were met with controversy. These receptor association with Autosomal Recessive Juvenile Parkinson positions it as a very attractive drug target, and as such its’ deorphanization is a prime objective for investigators in this area. Regarding MRGPRX3 information is much scarcer.
    [Show full text]
  • SCH 58261: a Potent and Selective Non-Xanthine A2A Adenosine Receptor Antagonist
    22 DIRECTED DRUG DISCOVERY™ LIGAND-SETS™ for Assay Validation and High Throughput Screening Easy-to-use collections of pharmacologically-similar, small organic ligands Sigma-RBI LIGAND-SETS™ are a convenient and affordable way to screen a specific target with a collection of well- characterized, pharmacologically-active compounds. Each LIGAND-SET™ contains 40-80 high purity (>96%), small organic ligands arranged by pharmacological class in a 96-well format, one compound (2 mg) per well (1 ml capacity). N Standardize/validate new screening assays with well-characterized ligands N Guide secondary screening of larger, diverse libraries using pharmaceutically-relevant structures N Screen new drug targets for leads with pharmacologically-active compounds Nine different LIGAND-SETS™ are now available: N Adrenergics (Prod. No. L 0383) N Enzyme Inhibitors (Prod. No. L 6787) N Purines/Pyrimidines (Prod. No. L 2538) N Cholinergics (Prod. No. L 2663) N GABAergics (Prod. No. L 7884) N Glutamatergics (Prod. No. L 6537) N Dopaminergics (Prod. No. L 6412) N Ion Channel Modulators (Prod. No. L 6912) N Serotonergics (Prod. No. L 6662) For further information, please visit our Drug Discovery website at sigma-aldrich.com/drugdiscovery Technical information for each compound is provided in standard SD file format for use with ISIS/Base or other compatible software (software not provided). SCH 58261: A potent and selective non-xanthine A2A adenosine receptor antagonist Vol. 19 No. 4 Vol. Adenosine (Prod. No. A 9251) acts as a modulator of [3]. These results suggest a neuroprotective effect of this neuronal activity through its interaction with four receptor compound. In another study, the role of A1 and A2A subtypes referred to as A1, A2A, A2B and A3.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Theophylline Level
    Lab Dept: Chemistry Test Name: THEOPHYLLINE LEVEL General Information Lab Order Codes: THEM Synonyms: Aminophylline, Theo-Dur, Slo-Bid CPT Codes: 80198 - Theophylline Test Includes: Theophylline concentration reported in mcg/mL. Logistics Test indications: Assessing and adjusting theophylline dosage for optimal therapeutic level. Assessing theophylline toxicity Theophylline is used to relax smooth muscles of the bronchial airways and pulmonary blood vessels to relieve and prevent symptoms of asthma and bronchospasm. Caffeine is a minor metabolite and is often seen in neonates taking theophylline. Peak levels are achieved in 30–90 minutes depending on the compound and type of preparation. Theophylline has a half-life of approximately 4 hours in children and adult smokers, and 8.7 hours in nonsmoking adults. Lab Testing Sections: Chemistry Referred to: Mayo Clinic Laboratories (MML Test: THEO) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Monday - Saturday Turnaround Time: 1 day Special Instructions: N/A Specimen Specimen Type: Blood Container: Preferred: Serum Gel (SST) Alternate: Red Top Draw Volume: 1.5 mL blood Processed Volume: 0.5 mL (Minimum: 0.25 mL) serum Collection: Routine blood collection Special Processing: Lab Staff: Centrifuge specimen within 2 hours of collection. Store and ship at refrigerated temperature. Patient Preparation: None Sample Rejection: Mislabeled or unlabeled specimen; gross hemolysis Interpretive Reference Range: Therapeutic: Bronchodilation: 8.0-20.0 mcg/mL Neonatal apnea (< or =4 weeks old): 6.0-13.0 mcg/mL Interpretation: Response to theophylline is directly proportional to the serum level. Patients usually receive the best response when the serum level is above 8.0 mcg/mL, with minimal toxicity experienced as long as the level is less than or equal to 20.0 mcg/mL Critical Values: >20.0 mcg/mL Limitations: Coadministration of cimetidine and erythromycin will significantly inhibit theophylline clearance, requiring dosagereduction.
    [Show full text]
  • Preladenant | Medchemexpress
    Inhibitors Product Data Sheet Preladenant • Agonists Cat. No.: HY-10889 CAS No.: 377727-87-2 Molecular Formula: C₂₅H₂₉N₉O₃ • Molecular Weight: 503.56 Screening Libraries Target: Adenosine Receptor Pathway: GPCR/G Protein Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 5 mg/mL (9.93 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 1.9859 mL 9.9293 mL 19.8586 mL Stock Solutions 5 mM 0.3972 mL 1.9859 mL 3.9717 mL 10 mM --- --- --- Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 0.5 mg/mL (0.99 mM); Suspended solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 0.5 mg/mL (0.99 mM); Suspended solution; Need ultrasonic 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.5 mg/mL (0.99 mM); Clear solution BIOLOGICAL ACTIVITY Description Preladenant is a potent and competitive antagonist of the human adenosine A2A receptor with a Ki of 1.1 nM and has over 1000-fold selectivity over other adenosine receptors. [1] IC₅₀ & Target Ki: 1.1 nM (Adenosine A2A receptor) In Vitro Preladenant also completely antagonizes cAMP in cells expressing the recombinant human A2A receptor. Preladenant is determined to has KB values of 1.3 nM at the A2A receptor; the value is in good agreement with the Ki value determined in Page 1 of 3 www.MedChemExpress.com the radioligand binding assay.
    [Show full text]
  • 1.Intro Corregida
    Heterómeros de receptores de dopamina como dianas terapéuticas en la enfermedad de Parkinson y en discinesias inducidas por el tratamiento con L-DOPA Daniel Farré Pérez ADVERTIMENT. La consulta d’aquesta tesi queda condicionada a l’acceptació de les següents condicions d'ús: La difusió d’aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d’investigació i docència. No s’autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d’un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s’autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora. ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB.
    [Show full text]
  • Aminophylline Catalog Number A1755 Storage
    Aminophylline Catalog Number A1755 Storage Temperature –20 °C Replacement for Catalog Number 216895 CAS RN 317-34-0 Storage/Stability Synonyms: theophylline hemiethylenediamine complex; Aminophylline should be kept tightly closed to prevent 3,7-dihydro-1,3-demethyl-1H-purine-2,6-dione CO2 absorption from the atmosphere, which leads to compound with 1,2-ethanediamine (2:1); formation of theophylline and decreased solubility in 1,2 3 (theophylline)2 • ethylenediamine aqueous solutions. Stock solutions should be protected from light and prevented from contact with Product Description metals.2 Molecular Formula: C7H8N4O2 ·1/2 (C2H8N2) Molecular Weight: 210.3 References 1. The Merck Index, 12th ed., Entry# 485. Aminophylline is a xanthine derivative which is a 2. Martindale: The Extra Pharmacopoeia, 31st ed., combination of theophylline and ethylenediamine that is Reynolds, J. E. F., ed., Royal Pharmaceutical more water soluble than theophylline alone. Society (London, England: 1996), pp. 1651-1652. Aminophylline has been widely used as an inhibitor of 3. Data for Biochemical Research, 3rd ed., Dawson, cAMP phosphodiesterase.3 R. M. C., et al., Oxford University Press (New York, NY: 1986), pp. 316-317. Aminophylline has been shown to limit 4. Pelech, S. L., et al., cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat phosphatidylcholine biosynthesis in cultured rat hepatocytes.4 It has been used in studies of acute hepatocytes. J. Biol. Chem., 256(16), 8283-8286 hypoxemia in newborn and older guinea pigs.5 The (1981). effect of various xanthine derivatives, including 5. Crisanti, K. C., and Fewell, J. E., Aminophylline aminophylline, on activation of the cystic fibrosis alters the core temperature response to acute transmembrane conductance regulator (CFTR) chloride hypoxemia in newborn and older guinea pigs.
    [Show full text]
  • Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness
    Thorax: first published as 10.1136/thx.44.12.1022 on 1 December 1989. Downloaded from Thorax 1989;44:1022-1026 Effect of theophylline and enprofylline on bronchial hyperresponsiveness G H KOETER, J KRAAN, M BOORSMA, J H G JONKMAN, TH W VAN DER MARK From the Department ofPulmonology and Lung Function, University Hospital, Groningen; Pharma Bio Research, Assen; and Astra Pharmaceutica, Rijswijk, The Netherlands ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were (maximum difference 2-0 and 1 7 higher after theophylline and enprofylline than after placebo copyright. doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo.
    [Show full text]
  • Annexes to the EMA Annual Report 2009
    Annual report 2009 Annexes The main body of this annual report is available on the website of the European Medicines Agency (EMA) at: http://www.ema.europa.eu/htms/general/direct/ar.htm 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged. Contents Annex 1 Members of the Management Board..................................................... 3 Annex 2 Members of the Committee for Medicinal Products for Human Use .......... 5 Annex 3 Members of the Committee for Medicinal Products for Veterinary Use ....... 8 Annex 4 Members of the Committee on Orphan Medicinal Products .................... 10 Annex 5 Members of the Committee on Herbal Medicinal Products ..................... 12 Annex 6 Members of the Paediatric Committee................................................ 14 Annex 7 National competent authority partners ............................................... 16 Annex 8 Budget summaries 2008–2009 ......................................................... 27 Annex 9 European Medicines Agency Establishment Plan .................................. 28 Annex 10 CHMP opinions in 2009 on medicinal products for human use .............. 29 Annex 11 CVMP opinions in 2009 on medicinal products for veterinary use.......... 53 Annex 12 COMP opinions in 2009 on designation of orphan medicinal products
    [Show full text]
  • Pro-Aging Effects of Xanthine Oxidoreductase Products
    antioxidants Review Pro-Aging Effects of Xanthine Oxidoreductase Products , , Maria Giulia Battelli y , Massimo Bortolotti y , Andrea Bolognesi * z and Letizia Polito * z Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy; [email protected] (M.G.B.); [email protected] (M.B.) * Correspondence: [email protected] (A.B.); [email protected] (L.P.); Tel.: +39-051-20-9-4707 (A.B.); +39-051-20-9-4729 (L.P.) These authors contributed equally. y Co-last authors. z Received: 22 July 2020; Accepted: 4 September 2020; Published: 8 September 2020 Abstract: The senescence process is the result of a series of factors that start from the genetic constitution interacting with epigenetic modifications induced by endogenous and environmental causes and that lead to a progressive deterioration at the cellular and functional levels. One of the main causes of aging is oxidative stress deriving from the imbalance between the production of reactive oxygen (ROS) and nitrogen (RNS) species and their scavenging through antioxidants. Xanthine oxidoreductase (XOR) activities produce uric acid, as well as reactive oxygen and nitrogen species, which all may be relevant to such equilibrium. This review analyzes XOR activity through in vitro experiments, animal studies and clinical reports, which highlight the pro-aging effects of XOR products. However, XOR activity contributes to a regular level of ROS and RNS, which appears essential for the proper functioning of many physiological pathways. This discourages the use of therapies with XOR inhibitors, unless symptomatic hyperuricemia is present.
    [Show full text]
  • Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants
    MedDocs Publishers ISSN: 2638-1370 Annals of Clinical Nutrition Open Access | Mini Review Study of Adulterants and Diluents in Some Seized Captagon-Type Stimulants Ali Zaid A Alshehri1,2*; Mohammed saeed Al Qahtani1,3; Mohammed Aedh Al Qahtani1,4; Abdulhadi M Faeq1,5; Jawad Aljohani1,6; Ammar AL-Farga7 1Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia 2Poison Control and Medical Forensic Chemistry Center, Ministry of Health, Riyadh, Saudi Arabia 3Khammis Mushayte Maternity & Children Hospital, Ministry of Health, Saudi Arabia 4Ahad Rufidah General, Hospital, Aseer, Ministry of Health, Saudi Arabia 5Comprehensive Specialized Clinics of Security Forces in Jeddah, Ministry of Interior, Saudi Arabia 6Compliance Department, Yanbu Health Sector, Ministry of Health, Saudi Arabia 7Department of Biochemistry, Faculty of Science, University of Jeddah, Saudi Arabia *Corresponding Author(s): Ali Zaid A Alshehri Department of Medical Laboratory Technology, College of Applied Medical Sciences, University of Jeddah, Saudi Arabia Email: [email protected] Received: Apr 27, 2020 Accepted: Jun 05, 2020 Published Online: Jun 10, 2020 Journal: Annals of Clinical Nutrition Publisher: MedDocs Publishers LLC Online edition: http://meddocsonline.org/ Copyright: © Alshehri AZA (2020). This Article is distributed under the terms of Creative Commons Attribution 4.0 International License Introduction ATS are synthetic compounds belonging to the class of stimu- and heroin users combined [3,4]. Fenethylline, 7-(2-amethyl lants that excite the Central Nervous System (CNS) to produce phenyl-amino ethyl)-theophylline, is a theophylline derivative of adrenaline-like effects such as amphetamine, methamphet- amphetamine. It is a psychoactive drug which is similar to am- amine, fenethylline, methylphenidate and dextroamphetamine phetamine in many ways [5].
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]